SET and MYND domain-containing protein 3 is overexpressed in human glioma and contributes to tumorigenicity

  • Authors:
    • Bin Dai
    • Weiqing Wan
    • Peng Zhang
    • Yisong Zhang
    • Changcun Pan
    • Guolu Meng
    • Xinru Xiao
    • Zhen Wu
    • Wang Jia
    • Junting Zhang
    • Liwei Zhang
  • View Affiliations

  • Published online on: September 1, 2015     https://doi.org/10.3892/or.2015.4239
  • Pages: 2722-2730
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

SET and MYND domain-containing protein 3 (SMYD3) is a histone H3 lysine 4 (H3K4) di- and tri-methyltransferase that forms a transcriptional complex with RNA polymerase II and plays an important role in early embryonic lineage commitment through the activation of lineage-specific genes. SMYD3 activates the transcription of oncogenes and cell cycle genes in gastric and breast cancer cells. However, the contribution of SMYD3 in glioma tumorigenesis remains unknown. Here, we determined the expression of SMYD3 and assessed its clinical significance in human glioma. We found that SMYD3 was overexpressed in human glioma but not in normal brain tissue. The level of SMYD3 protein expression in human glioma tissues was directly correlated with the glioma grade. The level of SMYD3 protein expression in human glioma tissues was inversely correlated with patient survival. Enforced SMYD3 expression promoted glioma LN-18 cell proliferation. Inhibition of SMYD3 expression in glioma T98G cells suppressed their anchorage‑independent growth in vitro and tumorigenicity in vivo. Furthermore, we found that SMYD3 regulated the expression of p53 protein, which is essential in SMYD3‑induced cell growth in glioma cells. These results showed that SMYD3 is overexpressed in human glioma and contributes to glioma tumorigenicity through p53. Therefore, SMYD3 may be a new potential therapeutic target for human malignant glioma.
View Figures
View References

Related Articles

Journal Cover

November-2015
Volume 34 Issue 5

Print ISSN: 1021-335X
Online ISSN:1791-2431

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Dai B, Wan W, Zhang P, Zhang Y, Pan C, Meng G, Xiao X, Wu Z, Jia W, Zhang J, Zhang J, et al: SET and MYND domain-containing protein 3 is overexpressed in human glioma and contributes to tumorigenicity. Oncol Rep 34: 2722-2730, 2015
APA
Dai, B., Wan, W., Zhang, P., Zhang, Y., Pan, C., Meng, G. ... Zhang, L. (2015). SET and MYND domain-containing protein 3 is overexpressed in human glioma and contributes to tumorigenicity. Oncology Reports, 34, 2722-2730. https://doi.org/10.3892/or.2015.4239
MLA
Dai, B., Wan, W., Zhang, P., Zhang, Y., Pan, C., Meng, G., Xiao, X., Wu, Z., Jia, W., Zhang, J., Zhang, L."SET and MYND domain-containing protein 3 is overexpressed in human glioma and contributes to tumorigenicity". Oncology Reports 34.5 (2015): 2722-2730.
Chicago
Dai, B., Wan, W., Zhang, P., Zhang, Y., Pan, C., Meng, G., Xiao, X., Wu, Z., Jia, W., Zhang, J., Zhang, L."SET and MYND domain-containing protein 3 is overexpressed in human glioma and contributes to tumorigenicity". Oncology Reports 34, no. 5 (2015): 2722-2730. https://doi.org/10.3892/or.2015.4239